PT - JOURNAL ARTICLE AU - Frank H. Hezemans AU - Noham Wolpe AU - Claire O’Callaghan AU - Rong Ye AU - Catarina Rua AU - P. Simon Jones AU - Alexander G. Murley AU - Negin Holland AU - Ralf Regenthal AU - Kamen A. Tsvetanov AU - Roger A. Barker AU - Caroline H. Williams-Gray AU - Trevor W. Robbins AU - Luca Passamonti AU - James B. Rowe TI - Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes AID - 10.1101/2021.07.04.21259922 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.04.21259922 4099 - http://medrxiv.org/content/early/2021/07/06/2021.07.04.21259922.short 4100 - http://medrxiv.org/content/early/2021/07/06/2021.07.04.21259922.full AB - Apathy is a debilitating feature of many diseases, including Parkinson’s disease. We tested the hypothesis that degeneration of the locus coeruleus-noradrenaline system contributes to apathy by modulating the relative weighting of prior beliefs about action outcomes. Participants with mild-to-moderate idiopathic Parkinson’s disease (N=17) completed a double-blind, placebo-controlled, crossover study with 40 mg of the noradrenaline reuptake inhibitor atomoxetine. Prior weighting was inferred from psychophysical analysis of performance in an effort-based visuomotor task, and was confirmed as negatively correlated with apathy. Locus coeruleus integrity was assessed in vivo using magnetisation transfer imaging at 7T. The effect of atomoxetine depended on locus coeruleus integrity: participants with a more degenerate locus coeruleus showed a greater increase in prior weighting on atomoxetine versus placebo. The results indicate a contribution of the noradrenergic system to apathy and potential benefit from noradrenergic treatment of people with Parkinson’s disease, subject to stratification according to locus coeruleus integrity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRegistered on ISRCTN registry with study ID ISRCTN46299660 (https://doi.org/10.1186/ISRCTN46299660). The study was retrospectively registered because it was exempt from Clinical Trials status by the UK Medicines and Healthcare Products Regulatory Authority (MHRA). However, we have endeavoured to retrospectively register it in order to meet compliance requirements for preprint and journal submissions.Funding StatementThe study was funded by the UK Medical Research Council (SUAG/051 G101400); the Wellcome Trust (220258); Parkinson's UK (K-1702); the Cambridge Centre for Parkinson-Plus (RG95450); the James S McDonnell Foundation (21st Century Science: Understanding Human Cognition); the NIHR Clinical Research Facility and Cambridge Biomedical Research Centre (BRC-1215-20014); a Cambridge Trust Vice-Chancellor's Award and Fitzwilliam College scholarship; an NIHR Academic Clinical Fellowship; a Neil Hamilton Fairley Fellowship from the Australian Mental Health and Medical Research Council (GNT1091310); the Holt Fellowship (RG86564); the Association of British Neurologists, Patrick Berthoud Charitable Trust (RG99368); the British Academy (PF160048); the Guarantors of Brain (101149); and an RCUK/UKRI Research Innovation Fellowship awarded by the UK Medical Research Council (MR/R007446/1). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Health Research Authority East of England - Cambridge Central Research Ethics Committee (REC 10/H0308/34)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and de-identified data to reproduce statistical analyses, computational modelling and manuscript figures will be made freely available through the Open Science Framework upon acceptance for journal publication.